EASL 2026 Reflections: Key takeaways in late-onset genetic cholestasis and Alagille syndrome
Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.
Observational data show IBAT inhibitor promise for pruritus in late-onset PFIC and ICP
Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.
Intrahepatic cholestasis of pregnancy recurs in 4 in 10 pregnancies
Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.
Targeted gene sequencing panel resolves unexplained cholestasis in about 5% of adults
A targeted next generation sequencing gene panel could offer a definitive diagnosis for some adults with unexplained cholestasis.
Researchers call for ICP to be included in hepatobiliary risk stratification
Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.
IBAT inhibitors may improve post-liver transplant pruritus
Treatment-refractory pruritus following liver transplant may be successfully treated with IBAT inhibitors, suggests a US case series.
Contraceptives linked to unique cholestatic phenotype
Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.
